Pfizer, Merck topped the Dow in 2018 despite biopharma declines by Arlene Weintraub Wednesday, January 2, 2019 Key oncology wins helped drive Pfizer and Merck to the top of the Dow in 2018, but the pharma sector faces plenty of hurdles this year.
Merck extends lung-cancer lead with Keytruda combo win by Carly Helfand Tuesday, January 16, 2018 Investors worried last year that Merck couldn’t replicate its Keytruda-chemo combo success in a phase 3 trial. But it just did.
Lilly wards off another Alimta patent challenge by Carly Helfand Friday, October 6, 2017 Eli Lilly has already foiled wannabe generic Alimta makers in court—and now it’s prevailed over one company taking the inter partes review route, too.
Mylan blasts Allergan's tribal licensing deal on Restasis by Eric Sagonowsky Wednesday, September 13, 2017 Mylan called Allergan's Restasis licensing agreement "desperate" and a "transparent" delay tactic in a federal court filing.
U.K. Supreme Court hands Eli Lilly big win in Alimta EU patent battle by Eric Palmer Friday, July 7, 2017 The U.K. Supreme Court has handed Eli Lilly a huge patent victory for its cancer drug Alimta in a battle with Actavis, protecting some European sales.
Pressure mounts on BMS, AZ as Merck bags Keytruda chemo combo OK by Carly Helfand Wednesday, May 10, 2017 Your move, Bristol-Myers Squibb and AstraZeneca. Merck’s Keytruda-chemo combo has its first-line lung cancer approval.
Lilly’s Alimta dodges patent blow by Eric Sagonowsky Thursday, January 12, 2017 An appeals court ruled against generics challenger Teva, potentially protecting Eli Lilly's cancer med Alimta until 2022.
University sues for a share of Gilead's hep C blockbusters by Tracy Staton Wednesday, August 31, 2016 The University of Minnesota wants a piece of Gilead’s hep C business. The school sued for patent infringement Monday, seeking royalties on the drugs’ multibillion-dollar sales.
